Balstilimab + Botensilimab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microsatellite Stable Rectal Carcinoma
Conditions
Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma
Trial Timeline
Feb 20, 2025 → Feb 20, 2028
NCT ID
NCT06843434About Balstilimab + Botensilimab
Balstilimab + Botensilimab is a phase 2 stage product being developed by Agenus for Microsatellite Stable Rectal Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06843434. Target conditions include Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07152821 | Phase 3 | Recruiting |
| NCT06843434 | Phase 2 | Recruiting |
Competing Products
11 competing products in Microsatellite Stable Rectal Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| Evorpacept (ALX148) + Cetuximab + Pembrolizumab | Eli Lilly | Phase 2 | 52 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| MK-3475 + INCB024360 | Merck | Phase 1/2 | 41 |
| AMG 436 | Amgen | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Copanlisib + Nivolumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016 | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |